GlassScriptPhysician profile
Alexandra Ingram
NPI 1730843194
$10,020.60
in general payments reported to CMS, 2019-2025
15 companies · $6,588 in 2025
The $6,588 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,524 · 2023: $476 · 2024: $432 · 2025: $6,588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,628 · Consulting Fee: $2,582 · Food and Beverage: $2,187 · Education: $98.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,628.03 |
| Consulting Fee | $2,582.25 |
| Food and Beverage | $2,187.49 |
| Education | $98.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,821.98 | 2025 | |
| Medtronic, INC. | $2,344.18 | 2024-2025 | Percept PC Brainsense |
| Boston Scientific Corporation | $1,839.42 | 2022-2023 | |
| Abbott Laboratories | $905.95 | 2022 | |
| Acadia Pharmaceuticals INC | $377.34 | 2023-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $183.11 | 2025 | |
| Polynovo North America LLC | $153.55 | 2025 | Novosorb Btm |
| Amneal Pharmaceuticals LLC | $135.00 | 2024 | Crexont |
| Mdd US Operations, LLC | $70.89 | 2024-2025 | Apokyn |
| Teva Pharmaceuticals USA, INC. | $62.65 | 2025 | Austedo Xr |
| Kyowa Kirin, INC. | $45.82 | 2024 | Nourianz |
| Coloplast Corp | $23.86 | 2024 | |
| Lilly USA, LLC | $22.27 | 2025 | Zepbound |
| Merz Pharmaceuticals, LLC | $17.51 | 2025 | Inbrija |
| Cala Health, INC. | $17.07 | 2025 | Cala Kiq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Ingram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.